Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001035922 | SCV001199262 | pathogenic | not provided | 2024-01-08 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Lys255*) in the ERCC6 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in ERCC6 are known to be pathogenic (PMID: 18628313, 29572252). This variant is present in population databases (no rsID available, gnomAD 0.006%). This variant has not been reported in the literature in individuals affected with ERCC6-related conditions. ClinVar contains an entry for this variant (Variation ID: 835111). For these reasons, this variant has been classified as Pathogenic. |
Ambry Genetics | RCV002551343 | SCV003589347 | pathogenic | Inborn genetic diseases | 2021-12-03 | criteria provided, single submitter | clinical testing | The c.763A>T (p.K255*) alteration, located in exon 5 (coding exon 4) of the ERCC6 gene, consists of an A to T substitution at nucleotide position 763. This changes the amino acid from a lysine (K) to a stop codon at amino acid position 255. This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. Based on the available evidence, this alteration is classified as pathogenic. |
Fulgent Genetics, |
RCV005047218 | SCV005681646 | likely pathogenic | DE SANCTIS-CACCHIONE SYNDROME; Cerebrooculofacioskeletal syndrome 1; Cockayne syndrome type 2; UV-sensitive syndrome 1; Age related macular degeneration 5; Premature ovarian failure 11; Lung cancer | 2024-02-17 | criteria provided, single submitter | clinical testing |